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ABSTRACT: Immune checkpoint blockade is one of the most promising strategies of
cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely
based on expensive monoclonal antibodies, which often inflict immune-related adverse
events. Herein, we propose a novel small-molecule inhibitor targeted at the most clinically
relevant immune checkpoint, PD-1/PD-L1. The compound is capable of disrupting the PD-
1/PD-L1 complex by antagonizing PD-L1 and, therefore, restores activation of T cells
similarly to the antibodies, while being cheap in production and possibly nonimmunogenic.
The final compound is significantly smaller than others reported in the literature while being
nontoxic to cells even at high concentrations. The scaffold was designed using a structure−
activity relationship screening cascade based on a new antagonist-induced dissociation NMR
assay, called the weak-AIDA-NMR. Weak-AIDA-NMR finds true inhibitors, as opposed to
only binders to the target protein, in early steps of lead compound development, and this
process makes it less time and cost consuming.
■ INTRODUCTION
Programmed cell death protein 1 (PD-1, known also as CD279)
and its ligand (PD-L1, known also as CD274 or B7-H1) are
transmembrane receptors involved in the negative regulation of
the activated T cells. The interaction of PD-1 with PD-L1
induces T cell apoptosis, anergy, and functional exhaustion.1,2
Some aggressive cancers, including breast, pancreatic cancers,
and nonsmall-cell lung carcinomas, are known to overexpress
PD-L1, which allows cancer to evade the immune response by
suppressing the adaptive immune system. The constitutive
overexpression of PD-L1 on cancer cells reduces activation and
proliferation of cancer-reactive T cells and induces T cells
apoptosis. Consequently, disrupting the PD-1/PD-L1 complex
at the cancer cell-T cell interface has become an attractive
strategy of cancer immunotherapy and was awarded a Nobel
Prize in Physiology or Medicine in 2018.3 Immune checkpoint
blockade-based therapies using monoclonal antibodies were
shown potent in numerous clinical trials for patients with a
broad spectrum of cancers, and these therapies delivered
antitumor responses and long-term remissions.4−9
The global Checkpoint Inhibitors Market in 2018 was
estimated to be almost $15 billion and predicted to grow to
$26 billion by 2023.10 It is solely based, though, on monoclonal
antibodies (mAbs) with three PD-1 inhibitors (pembrolizumab,
nivolumab, and cemiplimab) and three PD-L1 inhibitors
(avelumab, atezolizumab, and durvalumab) approved by the
U.S. Food and Drug Administration and The European
Medicines Agency for various types of cancers, such as bladder,
head and neck cancers, and kidney cancer, etc.11,12 Additionally,
there are over 1500 different clinical studies on PD-1/PD-L1
agents as of 2017, comprising mostly combination therapies
with other targeted therapies and/or chemotherapy aiming at
the discovery of synergistic effects. This clearly indicates how
rapidly growing is the PD-1/PD-L1 immunotherapy market.13
Despite their proven efficacy, mAbs-based therapies are
struggling with limitations including high treatment price,
immune-related adverse events (irAEs), and poor tumor
penetration related to their large size (150 kDa).14,15 A way to
overcome these shortcomings is presented with small-molecule-
based therapeutics, which due to their size (usually below 0.5
kDa) would be orally bioavailable and cheaper in manufacturing
while presenting improved pharmacokinetics and diffusion
rates.16 Even though there are plenty of patents regarding
potent small-molecules targeted at PD-L1,17−20 the only small
molecule intended to target at PD-L1 currently in clinical trials is
CA-170 from Curis and Aurigene, which is tested for the
treatment of advanced solid tumors and lymphomas
(NCT02812875, clinicaltrials.gov) and phase II clinical trials
for lung cancer, head and neck/oral cavity cancer, MSI-H
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positive cancers, and Hodgkin lymphoma in India (CTRI/
2017/12/011026, ctri.nic.in). Three groups, including ours,
have recently shown, however, that CA-170 is not a direct PD-
L1-binder, which was evidenced in several independent
biophysical and cell-based assays.21−23
The PD-1/PD-L1 interface is a challenging target due to its
large, flat, and hydrophobic interface with a poorly defined
binding pocket.24 A popular way to approach such problematic
targets is to use in silico screening further verified with a
biophysical assay to eliminate false-positive “hits”. However, to
analyze the impact of chemical modifications on the inhibitor
potency is nontrivial. One can predict how single changes will
modify the chemical properties of the analyzedmolecule, such as
its solubility, hydrophobicity, etc., but we can only speculate
how it will affect its interactions with the target protein.
Therefore, an array of different modifications is usually applied
to compare their influence on the final potency of the drug.
In the present study, we developed novel small-molecule
inhibitors targeted at human PD-L1 that is potent in disrupting
the PD-1/PD-L1 complex in biophysical and cell-based assays.
To identify these inhibitors, we established a structure−activity
relationship (SAR) screening cascade that is based on a new
antagonist-induced dissociation assay nuclear magnetic reso-
nance (NMR) screen, called weak-AIDA-NMR (w-AIDA-
NMR).25 w-AIDA-NMR facilitated the hit-to-lead design of
the compounds capable of dissociating the preformed PD-1/
PD-L1 complex. As compared to regular AIDA-NMR,24,26,27
herein we used an N66Amutant of PD-1 that increases the Kd of
the complex from 8 to ca. 100 μM, which hence allows small
molecules, which are typically low-affinity binders, to be
competitive in the complex formation. This was further followed
by selectivity assays and structural biology directed medicinal
chemistry design. The final compound 2k was intended to be as
small as possible and water-soluble, despite bearing two halogen
atoms, while fulfilling other requirements from Lipinski’s rule of
five. In parallel, we perform in silico screening to guide the
selection of the intermediate compounds.
■ RESULTS AND DISCUSSION
Identification of Fragments That Bind to PD-L1. The
only small-molecule, nonpeptidic inhibitors, for which cocrystal
structures with PD-L1 were reported, are based on a biphenyl
core.17,18,27 Because in silico design requires a high-resolution
structure of the target, we used this common feature as a starting
point for our SAR analysis. To find a seed fragment that could
lead to the PD-L1 inhibitory compound, we conducted a w-
AIDA-NMR screen on the available in-house library of
decorated biphenyl compounds (data not shown). In parallel,
we used a dimeric structure of PD-L1 with BMS-1166 bound
(PDB ID: 5NIX) for in silico screening with AutoDock Vina28
integrated into PyRx software to identify plausible beneficial
chemical modification.29 From our in silico screening, we
learned that a bromine, fluorine, or chlorine substitution
decreased the binding affinity from −9.3 kcal/mol for 3-
(bromomethyl)-1-1′-biphenyl to −9.8 kcal/mol, whereas
hydroxyl and nitriles reduce the potency of the scaffold that
indicates that the patch has to be hydrophobic. To validate the in
silico predictions, we characterized selected compounds using
the homogeneous time-resolved fluorescence (HTRF) assay
(Figure 1). The IC50 values of 1a and 1c were determined to be
around 51 and 56 μM, respectively, which is impressive for such
small fragments with acceptable water solubility (Table S1).
Moreover, the results of HTRF come in hand with our in silico
screening where compounds 1a and 1cwere themost prominent
examples.
Because HTRF is prone to “false positives”, especially
aggregators and autofluorophores, we validated the results
using the w-AIDA-NMR assay developed by us. In this assay, we
introduced a mutation in the PD-1 binding pocket that
effectively lowered its affinity toward PD-L1 so that short
fragments could dissociate it. The mutation does not affect the
PD-L1 binding interface to its inhibitors as described in detail in
our methodology paper.25 In the w-AIDA-NMR 2D experiment,
15N mutated PD-1 gives a characteristic pattern of peaks (Figure
2A). Peak assignment is not necessary as we observe a relative
change in the intensity and positions of the reference peaks upon
the addition of ligand/inhibitors. Upon the formation of the
complex with PD-L1, most of the cross-peaks in the 1H−15N
HMQC spectrum of PD-1 became broader and less intense with
some of the cross-peaks disappearing (Figure 2B). If the
inhibitor is capable of disrupting the complex, the resulting
spectrum should come back to the reference one of PD-1 alone,
as tested inhibitors are PD-L1 binders. Out of the tested
compounds, only bromine- and fluorine-substituted biphenyls
(1a and 1c) were capable of dissociating the mutant PD-1/PD-
L1 complex at equimolar concentrations in the w-AIDA-NMR,
which confirmed them not only to be binders but also putative
seeds for lead inhibitory compounds as well (Figure 2C and D,
respectively). Similar observations can be made using a 1D
version of the w-AIDA-NMR, however, with nonlabeled, and
hence cheaper to produce, protein. A characteristic aliphatic
spectrum of PD-1 and PD-L1 is presented in Figure 2E, blue and
red, respectively, with the most important PD-1 peaks
highlighted with gray bars. Upon the complex formation
(green curve), the highlighted peaks are flattened. However,
after the addition of equimolar concentrations of 1a and 1c,
those characteristic PD-1 peaks are restored indicating the
dissociation of PD-L1 from the complex (purple and orange
curves, respectively). Unambiguous identifications of short
fragments potent to dissociate a PD-1/PD-L1 complex would
not be possible using wild-type proteins, due to the too high
binding constant between inhibitor and PD-L1 as presented in
Figure S1.
Having the potential seed compounds identified, we
continued with the second SAR step using in silico screening
by designing the modification starting with the 2-bromo-3-
(bromomethyl)-1,1′-biphenyl (calculated binding affinity of
−10.2 kcal/mol). Because the biphenyl moiety is known to
position resulting molecules within the cleft between the two
PD-L1 units, we first decorated the phenoxymethyl with
halogens and O-ether benzonitrile or the corresponding
pyridine-cyanide to enhance the specificity of the binding by
Figure 1.Comparison of selected short biphenyl-based initial scaffolds.
BA stands for binding affinity.
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increasing the number of hydrogen donors/acceptors. To our
surprise, we found two potent populations of compounds with
the phenoxymethyl ring substituted with chlorine and O-ethers
in the para position and bromine without ether substitution. As
the last step, we tested various solubilizers to improve the water
solubility of the scaffold, which would not decrease the potency,
that resulted in final formulations of binding affinity between
−10.5 and −11.5 kcal/mol.
After in silico identification of potential beneficial extension,
we synthesized a group of compounds based on the 2-bromo-3-
(bromomethyl)-1,1′-biphenyl moiety (2a−k) collected in Table
1. First, 2-bromo-3-(bromomethyl)-1,1′-biphenyl (1a) O-
alkylation of various aldehydes in the presence of potassium
carbonate was performed. Next, isolated aldehydes (2a−d) were
subjected to the reductive amination mediated by sodium
cyanoborohydride resulting in final structures (2g−k). In the
case of compound 2f, we performed a Williamson reaction
between compound 1a andmethyl 3-bromo-4-hydroxybenzoate
to isolate 2e as the intermediate. We then introduced the amine
component in the presence of DBU obtaining the final
compound 2f. All described compounds were tested in the
HTRF assay to assess their biological activities as PD-1/PD-L1
complex inhibitors. Not surprisingly, the solubilities of the
compounds heavily influence the resulting biological activities
with aldehydes (2a−d) being substantially weaker than the
corresponding scaffolds equipped with solubilizing groups
(Table S1). The best results were obtained for compounds
with a bromine at the R1 position called from herein “di-bromo”
with N-[2-(methylamino)ethyl]acetamide (2g) and pipecolic
acid (2k) both exhibiting favorable low nanomolar IC50 values.
To extend the pool of functional groups, we tested a second
generation of compounds based on 2-bromo-3-(bromomethyl)-
1,1′-biphenyl (1a), [1,1′:2′,1″-terphenyl]-3′-ylmethanol (1b)
resulting in compounds 3b−d, 3f (Table 2) and based on 1d and
1e−g fragments (Table 3). We included 1b, 1d, and 1e−g
fragments to further validate if initial screening using w-AIDA-
NMR did not omit a potential hit. The synthesis started with the
Mitsunobu reaction or the Williamson etherification of short
fragment 1a or 1b with 5-chloro-2,4-dihydroxybenzaldehyde
resulting in 3a and 3e intermediates. To prepare compounds
3b,c,f, O-alkylation of phenolic aldehydes (3a, 3e) with 4-
(bromomethyl)picolinonitrile or 3-(bromomethyl)benzonitrile
was carried out. The NaBH3CN-mediated reductive amination
was used to convert aldehyde 3b into compound 3d, but
unexpectedly the product resulted to be unstable, without the
possibility to isolate the pure compound (purity 64%). Similar
reactions on other aldehyde substrates (3a, c, e, and f) were
unsuccessful, which limited the possibility to compare the
compounds’ bioactivities. Clearly, the addition of bulky 4-
(hydroxymethyl)pyridine-2-carbonitrile or 3-(hydroxymethyl)-
benzonitrile at the position R2 is favorable as they increase the
number of hydrogen donors, however at the cost of the
significantly higher molecular weight. Moreover, even though
that structure of compound 3d has already been disclosed in the
patent WO2017202275A1 (example 3), the modifications that
we did around it are not. Interestingly, our in silico screening
routine failed to find more potent compounds reported in this
patent, which proved that computational screening is still far
from perfect and requires a thorough validation of the results
with biophysical methods.
The preparation of inhibitors based on 1e−g fragments
comprised a synthetic pathway similar to that previously
described. After the Williamson ether synthesis, a series of
aldehydes (4a,g,i,m) or alcohol (4m) was isolated. The
performance of sodium cyanoborohydride-mediated reductive
amination with various amine components led to the conversion
of aldehydes (4a,g,i,m) into final compounds (4b,h,j,k,l). To
prepare the compound 4n, the conversion of (3-((2-bromo-
[1,1′-biphenyl]-3-yl)methoxy)phenyl)methanol (4m) to the
corresponding chloride and a nucleophilic substitution with a
thiomorpholine 1,1-dioxide was followed. Two other 1,1′:2′,1″-
terphenyl- and 6-(2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]-
dioxine-based aldehydes (4c,e) were obtained by the potassium
Figure 2.w-AIDA-NMRHSQC (A−D) and 1DNMR spectra (E). (A)
N66A-PD-1 w-AIDA, five groups of characteristic peaks are boxed in
green; (B) N66A-PD-1/PD-L1 complex, part of the PD-1 peaks
disappeared, boxed in red; (C) N66A-PD-1/PD-L1 complex + 1a, after
addition of compound 1a the spectrum of N66A-PD-1/PD-L1 complex
resembles spectrum A; all PD-1 peaks are restored indicating the
displacement of PD-L1 from the complex (peaks boxed in green); (D)
N66A-PD-1/PD-L1 complex + 1c spectrum resembles spectrum A; all
PD-1 peaks are restored indicating the displacement of PD-L1 from the
complex; (E) aliphatic part of the 1D NMR spectrum: blue, a
characteristic spectrum of N66A-PD-1 is highlighted with gray bars;
red, PD-L1spectrum, peaks in highlighted regions differ; green,
spectrum of N66A-PD-1/PD-L1 complex, spectrum becomes flattened
due to complex formation; purple, N66A-PD-1/PD-L1 complex + 1a,
restoration of characteristic PD-1 peaks due to addition of 1a inhibitor;
orange, N66A-PD-1/PD-L1 complex + 1c, restoration of characteristic
PD-1 peaks due to addition of 1c inhibitor.
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carbonated promoted O-alkylation of 3-bromo-4-hydroxyben-
zaldehyde with 1b and 1d chlorides. The last step involved the
NaBH3CN-mediated reductive amination resulting in potential
inhibitors 4d and 4f.
Because of the presence of two halogens and the solubilizer
group, none of our best compounds passed Lipinski’s rule of five,
mainly due to the violation of mass and/or hydrophobicity
requirements as calculated with the software Chemicalize
(Table S1). However, the final compound 2k showed the
most promising overall parameters, being 90 Da smaller and
with a 100 Å3 van der Waals volume difference as compared to
the second-best 3d. Compounds 2k, 2j, and 2hwere additionally
subjected to the competitive enzyme-linked immunosorbent
assay (competitive ELISA) to compare their ability to dissociate
human PD-1/PD-L1 complex as compared to BMS-1166 (a
potent PD-1/PD-L1 inhibitor from Bristol-Myers Squibb Co.)
(Figure S2). According to the results, compound 2k is a stronger
inhibitor as compared to BMS-1166 (1.47 ± 0.05 and 28.04 ±
0.36 nM, respectively), which further proved the potency of our
final product.
NMR-Binding Assay. The direct binding of the most
prominent compounds 2k and 3d to the human PD-L1 was also
confirmed with a 1HNMRmethod (Figure S3). In the assay, the
addition of the tested molecules 2k and 3d caused a
characteristic dimerization of hPD-L1 that we observed for the
biphenyl compounds previously,27 evidenced by the broadening
of the NMR peaks in the aliphatic region of the 1H NMR
spectrum as compared to the NMR spectrum of the apo hPD-
L1.
Cell-Based Assay. The most prominent compounds from
HTRF assay were tested in the PD-1/PD-L1 immune
checkpoint blockade cell-based assay. In the assay, the PD-1/
PD-L1 interaction is provided by the cocultured artificial
antigen-presenting cells (aAPCs) and Jurkat reporter T cells.
The compounds that disrupt this interaction increase a TCR-
mediated activation of the Jurkat cells, evidenced by the
increased activity of luciferase. The luciferase activity thus
reflects the activation status of the Jurkat T cells.
Durvalumab, a clinically relevant PD-L1-blocking antibody,
released the TCR signaling with the EC50 value of 0.2 ± 0.06
nM, as revealed by the fitting of Hill’s equation to the
experimental data set (Figure 3). All of the tested compounds
were also able to increase the activation of the effector cells, but
at considerably higher concentration ranges than durvalumab.
For Hill’s equation fitting, the maximal response to durvalumab
was set as a maximum allowed activation of the Jurkat effector
cells, because for the other compounds the activation plateau
could not be reached. Out of the tested compounds, compound
2k provided the highest level of the Jurkat T cell activation (2.1-
fold at a 50 μM concentration of a compound in the assay) and
Table 1. General Pathway for the Synthesis of Bromo Mono-Substituted Compoundsb
a(A) Methyl 3-bromo-4-hydroxybenzoate, K2CO3, DMF, rt, overnight (45% for 2e); (B) amine component R3, DBU (25% for 2f).
bReagents and
conditions: (A) substituted 4-hydroxybenzaldehde, K2CO3, DMF, rt, overnight (43% for 2a, 39% for 2b, 38% for 2c, and 52% for 2d); (B) amine
component, NaBH3CN, AcOH, DMF, rt, overnight (53% for 2g, 65% for 2h, 56% for 2i, 72% for 2j, and 51% for 2k).
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the lowest EC50 value of 6.6± 0.8 μM(Figure 3). This activation
was much better than the activation observed for the patented
compound 3d (EC50 value of 12.2 ± 1.4 μM), for which
solubility problems in DMSO/water conditions were observed,
which disallowed data collection for the two highest
concentrations. Compound 2g showed activity similar to that
of 2k (EC50 value of 6.8± 1.1 μM). However, due to the toxicity
of the compound 2g, observed above 10 μM concentration, the
value had to be estimated on the basis of partial data. Other
compounds exhibit EC50 > 40 μM and low activation levels.
The final compound 2k was also found not to be toxic up to
100 μM final concentration in cell viability assay (Figure S4). As
compared to the BMS compounds tested in Skalniak et al.
(2017), Figure 2a,27 this is a significantly better result, as the
potent BMS-1166 decreased the viability of the cells by 50% at
40 μM concentration, while it decreased the viability of other
BMS compounds at even lower inhibitor concentrations.
The biological activity of the compound 2k was further
verified on the primary T cells. For this, peripheral blood
mononuclear cells (PBMCs) isolated from the blood of healthy
donors were contacted with hPD-L1 aAPCs to provide TCR-
mediated activation of T cells and the engagement of PD-1/PD-
L1 immune checkpoint. The cells were then analyzed with flow
cytometry following the gating for CD4+ and CD8+ T cells. The
blockade of the PD-1/PD-L1 immune checkpoint was expected
to increase the activation of T cells. In the experiment,
atezolizumab and compound 2k were used. Neither of the two
molecules was able to increase the expression of an early T-cell
activation marker, CD69 (not shown). Because the prolonged
activation of T cells leads to the increase of the expression of
immune checkpoint molecules,30 we have monitored the
expression of PD-1 protein itself as an indicator of the late T
cell activation and exhaustion. In fact, the treatment with both
the control antibody atezolizumab and the compound 2k led to a
significant increase of the expression of PD-1 receptor on the
surface of both CD4+ and CD8+ T cells (Figure 4). This
confirms the bioactivity of the compound 2k in the context of
primary T cells.
Cross-Reactivity of the PD-L1/PD-1-Blocking Small
Molecules for Human and Murine PD-L1. Several
compounds based on the biphenyl core were subjected to the
MiscroScale Thermophoresis (MST) experiment to determine
their cross-reactivity toward murine and human PD-L1’s. We
used both the human (for the positive control) and the murine
PD-L1 for 2k, 2i, 2g, and BMS-1166, and the murine anti-PD-
L1 antibody MIH-5 as the positive control for murine PD-L1
Table 2. General Pathway for the Synthesis of Extended 2-Bromo-3-(bromomethyl)-1,1′-biphenyl (1a) and [1,1′:2′,1″-
Terphenyl]-3′-ylmethanol (1b)-Based Compounds 3b−d, 3fa
aReagents and conditions: (A) for compound 1a where X is −Br, 5-chloro-2,4-dihydroxybenzaldehyde, NaHCO3, ACN/DMF, rt, overnight (54%
for 3a); for compound 1b where X is −OH, 5-chloro-2,4-dihydroxybenzaldehyde, PPh3, DIAD, THF, rt, overnight (20% for 3e); (B)
picolinonitrile/benzonitrile component, K2CO3, DMF, rt, overnight (63% for 3b, 87% for 3c, and 90% for 3f); (C) amine component, NaBH3CN,
AcOH, DMF, rt, overnight (for 3d).
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Table 3. General Pathway for the Synthesis of 6-(2-Bromo-3-(bromomethyl)phenyl)-2,3-dihydrobenzo[b][1,4]dioxine (1g),
1,1′:2′,1″-Terphenyl (1b), 6-(3-(Bromomethyl)-2-fluorophenyl)-2,3-dihydrobenzo[b][1,4]dioxine (1d), [1,1′:2′,1″-
Terphenyl]-3′-ylmethanol, 2-Bromo-3-(bromomethyl)-3′-fluoro-1,1′-biphenyl (1f), and 2′-Bromo-3′-(bromomethyl)-[1,1′-
biphenyl]-4-carbonitrile (1e)-Based Compounds 4a−na
aReagents and conditions: (A) for compounds 1e−g where X is −Br, substituted 4-hydroxybenzaldehde, K2CO3, DMF, rt, overnight (88% for 4a,
61% for 4g, 57% for 4i, and 52% for 4m); for compounds 1b, 1d where X is −OH, (1) SOCl2, DCM, 40 °C, (2) substituted 4-
hydroxybenzaldehde, K2CO3, DMF, rt, overnight (30% for 4c and 60% for 4e); (B) for compounds 4a,c,e,g,i, amine component, NaBH3CN,
AcOH, DMF, rt, overnight (43% for 4b, 61% for 4d, 37% for 4f, 26% for 4h, 44% for 4j, 67% for 4k, and 33% for 4l); for compounds 4m, (1)
SOCl2, DCM, 40 °C, (2) amine component, K2CO3, DMF, rt, overnight (29% for 4n).
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(Figure S5A−E, respectively). The experiment showed that the
compounds based on the biphenyl moiety were not active
against the murine PD-L1, as they did not cause any changes in
the fluorescence spectrum upon addition to the protein solution,
whereas they have a clear pattern when tested against the human
PD-L1, with 2k and 2g being the tighter binders (dissociation
constants KD of 4.0 and 3.2 nM, respectively) than BMS-1166
(KD of 30.3 nM) (Table S2). This MST result disqualifies the
biphenyl-based compounds for the experiments on the
syngeneic mice as there is no cross-reactivity between human
and murine targets.
Modeled Interactions with Dimeric PD-L1. To explore
themolecular interactions of most potent compounds 2k and 3d
with PD-L1, we docked the compounds into a dimeric PD-L1
using the PyRx software. To refine the docking results, residues
interacting with those compounds were allowed flexibility in
their side chains. The interactions then were assessed using the
Protein−Ligand Interaction Profiler (Figure 5).31 The core of
the scaffold for both molecules is the same, with the biphenyl
structure positioning the molecules with its strong and
conserved stabilizing π−π stacking with Tyr56A and an aromatic
phenyl ring with Tyr56B. The hydrogen bonding of 2k comes
from the interactions between the Tyr56B hydroxyl group and
nitrogen atom from the pipecolic acidmoiety and Asn63B amide
nitrogen and oxygen from the carboxylic group of a solubilizer.
For 3d, hydrogen bonds are predicted between cyanopyridine
nitrogen with Arg125A nitrogen and nitrile group nitrogen with
Asn63B nitrogen. Clever usage of solubilizer in 2k allows for a
great reduction in molecule size by 90 Da, down to 557 Da
(close to the Lipinski’s size rule requirement <500 Da).
Moreover, the tertiary amine in solubilizers of both 3d and 2k
is predicted to be involved in salt bridges with the Asp122A
negatively charged carboxyl group stabilizing the whole
complex. Both compounds are also involved in several
hydrophobic interactions with residues Ile54A Tyr56A and B,
Gln66B,Met115B, and either Ala121A for 2k or Ala121B for 3d,
as well as Tyr123A that comes from the main scaffold (2a).
Figure 3. Activity of modified bromo compounds in PD-1/PD-L1 immune checkpoint blockade cell-based assay. Activities of the reference anti-PD-
L1 antibody durvalumab and tested compounds in alleviating the effect of PD-1/PD-L1 checkpoint on TCR-mediated effector Jurkat T cells are
expressed as fold induction of the luciferase activity, the expression of which is TCR-inducible (for details, please see the Experimental Section). The
graphs present relative luminescence normalized to DMSO-treated controls and are mean ± SEM values from 4 to 7 independent experiments.
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■ CONCLUSIONS
Herein, we demonstrate a new, potent compound that can
dissociate the PD-1/PD-L1 complex, with the potency of
inciting adaptive immune system and activating cancer-reactive
T cells. Our final compound 2k is significantly smaller than other
small-molecule inhibitors reported in the literature. The design
process was based on the novel methodology for the
identification of potent small-molecular fragments, with w-
AIDA-NMR as the starting block for further extensions. Tested
fragments were not able to dissociate the native PD-1/PD-L1
complex in AIDA-NMR (Figure S1), which proved the
usefulness of w-AIDA-NMR in the identification of small potent
fragments for inhibitors. w-AIDA-NMR offers unambiguity of
the results, due to the simplest system possible, protein and
compound in the buffer of your choice, and ensures that the core
fragment is capable of dissociating the complex. Moreover, using
this technique, one can instantly spot compounds that are
precipitating or aggregating the target protein as well as
controlling the solubility of the tested fragment, a common
issue in other biophysical assays. Because it is not based on the
modification of light, it will not generate “false positives”,
significantly reducing time and cost commitment in developing
“falsified hits”. Each intermediate step was validated with the
HTRF affinity determination and later with the cell-based assay.
The final compound 2kwas shown to bemore potent than other
molecules tested here and able to activate Jurkat cells to a degree
close to that of the control antibody. In fact, 2k is the strongest
small-molecule inhibitor of PD-L1 reported in the literature
including potent BMS-1166 and BMS-1001.27 Thanks to its
enhanced solubility and small size, 2k is neutral to cell viability
even at a 100 μM concentration. Because of the lack of cross-
reactivity between human andmurine PD-L1 for biphenyl-based
compounds, we were not able to perform experiments on mice.
However, we were able to prove the bioactivity of the compound
2k in the experiments with primary T cells isolated from the
blood of healthy donors by monitoring the expression of PD-1
receptor on the surface of both CD4+ and CD8+ T cells.
Figure 4. Compound 2k blocks the PD-L1/PD-1 immune checkpoint
in primary human T cells, as evidenced by the increased expression of
the late activation and exhaustion marker, PD-1. Peripheral blood
mononuclear cells (PBMCs) were seeded on the preseeded hPD-L1
aAPCs and cultured for 48 h alone or in the presence of 2k, DMSO (as a
solvent for 2k), or atezolizumab (atezo., an anti-PD-L1 therapeutic
antibody). The expression of PD-1 was tested with flow cytometry. (A)
Exemplary histograms, presenting the increased expression of PD-1 on
either the CD4+ or the CD8+T cells. (B) The analysis of the expression
of PD-1 on CD4+ or CD8+ T cells under control conditions and in the
presence of PD-L1-blocking molecules, the antibody atezolizumab, and
compound 2k. Graphs present mean ± SD values calculated for three
independent experiments performed with the engagement of different
donors. Statistical significance was analyzed with the Student’s t test: *p
< 0.05, **p < 0.01.
Figure 5. Interactions between PD-L1 and 3b (top) and 2k (bottom)
from modeled complexes (compounds were docked on PD-L1 taken
from PDB ID: 5NIX). Both compounds are involved in a number of
hydrophobic interactions (gray dashed lines) with residues Ile54A
Tyr56A and B, Gln66B, Met115B, Ala121A for 3b and Ala121B for 2h,
and Tyr123A. There is strong conserved stabilizing π-stacking (green
dashed line) between the distal phenyl ring from the biphenyl moiety
and Tyr56A and the phenyl from phenoxymethyl with Tyr56B. The
major differences are in the hydrogen bonds (blue solid line), which for
2k are between the Tyr56B hydroxyl group and the tertiary amine in
piperidine solubilizer and the Asn63B amide nitrogen and oxygen from
the carboxylic group of the solubilizer. For 3b, hydrogen bonds are
between the cyanopyridine nitrogen with Arg125A nitrogen and the
nitrile group nitrogen with Asn63B nitrogen.
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■ EXPERIMENTAL SECTION
Protein Expression and Purification. All chemicals used for
protein expression and purification were purchased from BioShop
(Bioshop Canada Inc., Burlington, ON, Canada) and Sigma-Aldrich
(Sigma-Aldrich Corporation, St. Louis, MO) and were used without
any additional purification. The IgV domains of human and mouse PD-
L1 protein (hPD-L1 residues, 18−134, C-terminal His-tag; mPD-L1
residues, 19−134) and the extracellular domain of human PD-1 (hPD-1
residues 34−150, C93S) were expressed and purified as described
previously.24 Proteins were expressed in the Escherichia coli BL21
(DE3). Bacterial cells were cultured at 37 °C in LB or M9 minimal
medium containing 15NH4Cl as the sole nitrogen source to achieve
15N
isotope labeling. Proteins expression was induced with 1mM osopropyl
β-D-1-thiogalactopyranosid (IPTG) at an OD600 of 0.8, and the cells
were cultured overnight. For hPD-1, the temperature was lowered to 28
°C. The inclusion bodies purification was carried out as described
previously.32 Afterward proteins were refolded by dropwise dilution
into a solution containing 0.1 M Tris pH 8.0, 0.4 M L-arginine
hydrochloride, 2 mMEDTA, 5 mM cystamine, and 0.5 mM cysteamine
for hPD-1, and 0.1 M Tris pH 8.0, 1 M L-arginine hydrochloride, 0.25
mM oxidized glutathione, and 0.25 mM reduced glutathione for hPD-
L1. After refolding, proteins were dialyzed three times against solution
containing 10 mMTris pH 8.0 and 20 mMNaCl. Finally, proteins were
purified by SEC (size-exclusion chromatography) on an HiLoad 26/
600 Superdex 75 column (GE Healthcare, Chicago, IL) in 25 mM
sodium phosphate pH 6.4 with 100 mMNaCl for hPD-1, N66A hPD-1
mutant or in PBS pH 7.4 for hPD-L1, hPD-L1(18−239).
AIDA-NMR. Uniform 15N labeling was obtained by expressing
proteins in the M9 minimal medium containing 15NH4Cl as the sole
nitrogen source. 10% (v/v) of D2Owas added to the samples to provide
the lock signal. All spectra were recorded at 300 K using a Bruker
Avance III 600 MHz spectrometer equipped with the nitrogen
cryoprobe. The ability of tested compounds to dissociate PD-L1/
(wild type, wt or N66A)PD-1 was evaluated using the (weak)
antagonist-induced dissociation assay (w-AIDA-NMR). In brief, 15N-
labeled wt- and N66A PD-1 (0.15 mM) were slightly overtitrated with
the unlabeled PD-L1. The compounds were aliquoted into the resulting
mixture. During the experiment, the 1H−15N signals were monitored by
SOFAST HMQC.
Homogeneous Time-Resolved Fluorescence.The HTRF assay
was performed using the certified Cis-Bio assay kit at 20 μL final volume
using their standard protocol (5 nM of hPD-L1 and 50 nM of hPD-1 in
the final formulation). To determine the half maximal inhibitory
concentration (IC50) of the tested compounds, measurements were
performed on individual dilution series. After all components were
mixed according to Cis-Bio protocol, the plate was left for 2 h
incubation at room temperature followed by TR-FRET measurement
on a Tecan Spark 20M. Collected data were background subtracted on
the negative control, normalized on the positive control, averaged, and
fitted with a normalized Hill’s equation to determine the IC50 value
using Mathematica 12.
Cell Culture. CHO K-1 cells overexpressing hPD-L1 and the
recombinant TCR ligand (hPD-L1 Antigen Presenting Cells, hPD-L1
aAPCs) (Promega, Madison, WI) and Jurkat T cells overexpressing
hPD-1 and carrying a luciferase reporter gene under the control of
Nuclear Factor of Activated T-cells Response Element (NFAT-RE)
(hPD-1 Effector Cells, hPD-1 ECs, Promega) were cultured in RPMI-
1640 medium (Biowest, Billerica, MA) supplemented with 10% Fetal
Bovine Serum (FBS, Biowest) and 200 mM L-glutamine (Biowest) in
the presence of G418 (250 μg/mL, InvivoGen, San Diego, CA) and
Hygromycin B Gold (50 μg/mL, InvivoGen) as selection antibiotics.
The overexpression of hPD-L1 and TCR ligand in aAPCs and PD-1 in
ECs was confirmed by flow cytometry and Western blot analysis,
respectively. PCR tests for Mycoplasma sp. contamination33 were
routinely performed and indicated negative results for both cell lines.
hPD-1/hPD-L1 Immune Checkpoint Blockade Assay. The
activity of the inhibitors of the hPD-1/hPD-L1 immune checkpoint was
examined using the hPD-1/hPD-L1 Blockade Bioassay (Promega),
according to the manufacturer’s instructions. hPD-L1 aAPCs were
seeded on 96-well (white) plates at the density 10 000 cells/well 17 h
prior to the experiment. The 2.5-fold dilution of the small molecules
was first prepared in DMSO. On the day of the assay, the compounds
were diluted 1000-fold in the assay buffer (99% RPMI 1640, 1% FBS)
to maintain the constant concentration of DMSO (0.1% of total
volume). The 2.5-fold dilutions of durvalumab, a positive control anti-
hPD-L1 monoclonal antibody (Imfinzi, Medimmune/AstraZeneca),
were prepared in the assay buffer on the day of the assay. The culture
medium was discarded from the wells, and serial dilutions of either the
small molecule or the antibody were added. Afterward, Jurkat hPD-1
cells were seeded at the density of 20 000 cells per well in the assay’s
plates. After 6 h of incubation in standard culture conditions, assay
plates were equilibrated at ambient temperature for 10 min, followed by
a 20 min incubation with the Bio-GloTM Assay reagent (Promega).
The luminescence was detected using the Spark microplate reader
(Tecan). Half maximal effective concentrations (EC50 values) were
calculated from Hill’s curve fitting to the experimental data.
Isolation of Peripheral Blood Mononuclear Cells (PBMCs).
Blood samples from healthy donors were purchased from the Regional
Center of Blood Donation and Blood Therapy in Krakow. PBMCs were
isolated by a density gradient centrifugation using Pancoll human
separating solutions (PAN-Biotech) and then resuspended in RPMI
1640 medium (Biowest) containing 10% FBS (Biowest).
Flow Cytometry Analysis of Activation Markers. PBMCs were
added to the preseeded aAPCs at the density of 400 000 cells/well and
incubated in the presence of compound 2k, DMSO, and with or
without atezolizumab (5 μg/mL) as an anti-PD-L1 monoclonal
antibody. After 48 h, cells were detached using TrypLe Select Enzyme
(Thermo Fisher Scientific), collected into 5 mL round-bottom tubes,
and washed with flow cytometry staining buffer (Thermo Fisher
Scientific). For flow cytometry analysis, cells were stained using
monoclonal antibodies: anti-CD69-APC, anti-CD4-FITC, anti-CD8-
BV510, and anti-PD1-PECy7 (Becton Dickinson, BD). Following 20
min of incubation at room temperature, cells were washed, resuspended
in PBS, and analyzed using a FACSCanto II flow cytometer (BD) and
FACSDiva software (BD). The data analysis was carried out with
FACSuite software (BD).
Molecular Docking and In Silico Screening. The compounds
were generated as a permutation of all (interesting to us) functional
groups on biphenyl scaffold (over 1500 structures), which were then
minimized using OpenBabel software. For molecular docking of
putative inhibitors, we used AutoDock Vina28 integrated into PyRx with
the dimeric structure of PD-L1 with BMS-1166 bound (PDB ID:
5NIX). On the basis of the scoring results and feasibility of chemical
synthesis, we selected the most interesting compounds.
Chemical Synthesis of Compounds. General Information.
Starting materials and solvents were received from Sigma-Aldrich, Cool
Pharm, Idalia, and Alfa Aesar, and they were used without additional
purification. 1H and 13C NMR spectra were recorded on a Bruker
Avance 600 MHz spectrometer with a report of chemical shifts (δ) in
ppm and coupling constants (J) in Hz. TMS was used as the reference
and an internal standard with a singlet at δ 0 ppm. Moreover, chemical
shifts were analyzed in correspondence to the solvent peaks (DMSO-d6,
CDCl3).
Infrared spectra were recorded for the solid samples on a Nicolet
IR200 spectrometer due to the ATR technique. High-resolution mass
spectrometry (HRMS) analysis was performed on a microTOF-QII
apparatus using the ESI ionization mode. Purification of compounds
was conducted thanks to flash chromatography on the Grace Reveleris
X2 Flash Chromatography System with Grace Resolv Silica Cartridges.
The UPLC−MSs were recorded on the TQD Waters H-Class
spectrometer (column, ACQUITY UPLC BEH C18 1.7 um, 2.1 ×
50 mm; method, 6 min; gradient, 0−3 min 80% H2O−20%MeCN, 3−
3.5 min 100% MeCN, 3.5−6 min 80% H2O−20% MeCN). All final
compounds were determined to have at least 95% purity. Thin-layer
chromatography (TLC) was performed thanks to use of aluminum
sheets precoated Silica Gel 60 F254 (Merck). Techniques of visual-
ization of TLC plates included using an UV lamp with radiation at 254
nm wavelength. Melting points were determined with an Ascon-M5
apparatus.
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The syntheses of substrates and the preparation of short fragments
1a−1g are described in the Supporting Information.
4-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)benzaldehyde (2a). 1a
(200 mg, 0.62 mmol), 4-hydroxybenzaldehyde (75 mg, 0.62 mmol),
and potassium carbonate (170 mg, 1.23 mmol) were stirred in
anhydrous DMF (3 mL) at room temperature overnight. The solvent
was removed under reduced pressure. Water was added (30 mL), and
themixture was extracted with AcOEt (2× 30mL). Organic layers were
combined and concentrated. Crude product was purified by column
chromatography on silica gel (0−100% AcOEt in hexane) and
crystallized from cyclohexane to yield 2a (97 mg, 43%) as a white
solid. 1HNMR (600MHz, CDCl3) δ: 9.91 (s, 1H), 7.90−7.86 (m, 2H),
7.54−7.51 (m, 1H), 7.47−7.37 (m, 6H), 7.31 (dd, J = 7.5, 1.7 Hz, 1H),
7.15−7.12 (m, 2H), 5.30 (s, 2H). 13C NMR (151 MHz, CDCl3) δ:
190.8, 163.4, 143.7, 141.1, 136.1, 132.1, 130.9, 130.4, 129.4, 128.1,
127.8, 127.5, 127.4, 122.6, 115.2, 70.4. IR (ATR): 2916, 2849, 2835,
1684, 1598, 1591 1508, 1422, 1260, 1164, 1046 cm−1. HRMSESI−MS-
q-TOF for C20H15BrO2 [M + Na]
+ found, 389.0148 m/z; calcd mass,
389.0153. Mp: 87.7 °C. UPLC−MS (DAD/ESI): tR = 8.78 min, for
C20H15BrO2 [M + H]
+ found, 367.18 m/z; calcd mass, 367.03.
3-Bromo-4-( (2-bromo-[1 ,1 ′ -biphenyl] -3-y l )methoxy)-
benzaldehyde (2b). Compound 2b was prepared following the
procedure for 2a. Preparation involved the use of 1a (220 mg, 0.68
mmol), 3-bromo-4-hydroxybenzaldehyde (136 mg, 0.68 mmol), and
potassium carbonate (187 mg, 1.36 mmol), which were stirred in
anhydrous DMF (3 mL) at room temperature overnight. Crude
product was purified by column chromatography on silica gel (0−100%
AcOEt in hexane) and yielded 2b (119 mg, 39%) as a white solid. 1H
NMR (600MHz, CDCl3) δ: 9.87 (s, 1H), 8.15 (d, J = 2.0 Hz, 1H), 7.83
(dd, J = 8.4, 2.0 Hz, 1H), 7.69 (d, J = 7.7 Hz, 1H), 7.49−7.37 (m, 6H),
7.32 (dd, J = 7.5, 1.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H), 5.36 (s, 2H). 13C
NMR (151 MHz, CDCl3) δ: 189.7, 159.5, 143.6, 141.1, 135.7, 134.8,
131.3, 131.3, 130.9, 129.6, 128.2, 127.9, 127.7, 127.2, 121.9, 113.4,
113.1, 71.1. IR (ATR): 3082, 2923, 2852, 1683, 1593, 1492, 1276,
1256, 1185, 1050 cm−1. HRMSESI−MS-q-TOF for C20H14Br2O2 [M+
Na]+ found, 466.9249 m/z; calcd mass, 466.9258. Mp: 151.2 °C.
UPLC−MS (DAD/ESI): tR = 9.37 min, for C20H14Br2O2 [M + H]+
found, 447.07 m/z; calcd mass, 446.94.
4-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)-3-methylbenzalde-
hyde (2c). Compound 2c was obtained according to the procedure of
2a, using 1a (200 mg, 0.62 mmol), 4-hydroxy-3-methylbenzaldehyde
(84 mg, 0.62 mmol), potassium carbonate (170 mg, 1.23 mmol), and
anhydrous DMF (3 mL). Crude product was purified by column
chromatography on silica gel (0−100% AcOEt in hexane) and was
crystallized from cyclohexane to yield 2c (90 mg, 38%) as a white solid.
1H NMR (600 MHz, CDCl3) δ: 9.88 (s, 1H), 7.76 (d, J = 1.1 Hz, 1H),
7.73 (dd, J = 8.3, 2.0 Hz, 1H), 7.57−7.53 (m, 1H), 7.47−7.38 (m, 6H),
7.32 (dd, J = 7.5, 1.7 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 5.30 (s, 2H),
2.41 (s, 3H). 13C NMR (151 MHz, CDCl3) δ: 191.3, 161.7, 143.7,
141.3, 136.6, 131.8, 130.8, 130.1, 129.6, 128.2, 128.1, 127.9, 127.5,
127.3, 122.5, 111.2, 70.4, 16.7. IR (ATR): 2821, 1679, 1599, 1260,
1240, 1125, cm−1. HRMS ESI−MS-q-TOF for C21H17BrO2 [M + Na]+
found, 403.0304m/z; calcd mass, 403.0309.Mp: 144.5 °C. UPLC−MS
(DAD/ESI): tR = 9.31 min, for C21H17BrO2 [M + H]
+ found, 381.20
m/z; calcd mass, 381.05.
4-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)-3-methoxybenzalde-
hyde (2d).Compound 2d was prepared following the procedure for 2a.
Preparation involved the use of 1a (300 mg, 0.93 mmol), 4-hydroxy-3-
methoxybenzaldehyde (141 mg, 0.93 mmol), and potassium carbonate
(255 mg, 1.85 mmol), which were stirred in anhydrous DMF (3 mL) at
room temperature overnight. Crude product was purified by column
chromatography on silica gel (0−100% AcOEt in hexane) and yielded
2d (192mg, 52%) as a white solid. 1HNMR (600MHz, CDCl3) δ: 9.87
(s, 1H), 7.53 (ddd, J = 10.8, 5.8, 5.0 Hz, 1H), 7.49−7.35 (m, 8H), 7.29
(dd, J = 7.5, 1.6 Hz, 1H), 7.01 (d, J = 8.2 Hz, 1H), 5.37 (s, 2H), 4.00 (s,
3H). 13CNMR (151MHz, CDCl3) δ: 191.1, 153.4, 150.2, 143.6, 141.3,
136.2, 130.8, 130.7, 129.6, 128.2, 127.8, 127.6, 127.3, 126.8, 122.2,
112.6, 109.6, 71.0, 56.3. IR (ATR): 2916, 2850, 2834, 1683, 1588, 1507,
1421, 1265, 1235, 1134, 1031 cm−1. HRMS ESI−MS-q-TOF for
C21H17BrO3 [M + Na]
+ found, 419.0253 m/z; calcd mass, 419.0259.
Mp: 109.0 °C. UPLC−MS (DAD/ESI): tR = 8.50 min, for C21H17BrO3
[M + H]+ found, 397.22 m/z; calcd mass, 397.04.
Methyl 3-Bromo-4-((2-bromo-[1,1′-biphenyl]-3-yl)methoxy)-
benzoate (2e). Compound 2e was prepared according to the protocol
for 2a. Preparation involved the use of 1a (200 mg, 0.61 mmol), methyl
3-bromo-4-hydroxybenzoate (142 mg, 0.61 mmol), and potassium
carbonate (169 mg, 1.22 mmol), which were stirred in anhydrous DMF
(3 mL) at room temperature overnight. Crude product was purified by
precipitation from AcOEt to give 2e (131 mg, 45%) as a white solid. 1H
NMR (600 MHz, CDCl3) δ: 8.30 (d, J = 2.1 Hz, 1H), 7.99 (dd, J = 8.6,
2.1 Hz, 1H), 7.71−7.68 (m, 1H), 7.47−7.38 (m, 6H), 7.30 (dd, J = 7.5,
1.7 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 5.32 (s, 2H), 3.90 (s, 3H). 13C
NMR (151 MHz, CDCl3) δ: 165.7, 158.3, 143.4, 141.1, 135.9, 135.0,
130.6, 129.5, 128.0, 127.7, 127.5, 127.1, 124.3, 121.8, 112.5, 112.1, 70.8,
52.2. IR (ATR): 2948, 2163, 1981, 1781, 1599, 1498, 1431, 1363, 1311,
1269, 1240, 1108, 1054 cm−1. HRMS ESI−MS-q-TOF for
C21H16Br2O3 [M + Na]
+ found, 496.9447 m/z; calcd mass, 496.9364.
Mp: 160.3 °C. UPLC−MS (DAD/ESI): tR = 9.99 min, for
C21H16Br2O3 [M + H]
+ found, 475.12 m/z; calcd mass, 474.95.
4-(3-(3-Bromo-4-((2-bromo-[1,1′-biphenyl]-3-yl)methoxy)-
benzamido)propyl)morpholin-4-ium Hydrochloride (2f). 2e (100
mg, 0.21 mmol) and DBU (350 μL) were stirred in 3-
morpholinopropan-1-amine (1.5 mL) at room temperature for 2
days. Afterward, the reaction mixture was solubilized with AcOEt (30
mL). Following that, water was added (30 × 2 mL) to wash out the
excess of amine from organic layers. Organic layers were dried,
combined, and concentrated. Purification involved column chromatog-
raphy on silica gel (0−10% CHCl3 in MeOH). After purification,
compound was converted into the corresponding hydrochloride salt,
and product was precipitated from AcOEt to give 2f (30 mg, 25%) as a
white solid. 1H NMR (600 MHz, CDCl3) δ: 8.14 (t, J = 4.0 Hz, 1H),
8.06 (d, J = 2.2 Hz, 1H), 7.82 (dd, J = 8.6, 2.2 Hz, 1H), 7.73−7.69 (m,
1H), 7.48−7.37 (m, 5H), 7.30 (dd, J = 7.5, 1.7 Hz, 1H), 7.03 (d, J = 8.6
Hz, 1H), 5.31 (s, 2H), 3.78 (t, J = 4.6 Hz, 4H), 3.57 (dd, J = 10.9, 5.8
Hz, 2H), 2.58 (t, J = 5.7 Hz, 2H), 2.53 (s, 4H), 1.84−1.74 (m, 2H). 13C
NMR (151 MHz, CDCl3) δ: 165.6, 157.1, 143.5, 141.2, 136.2, 132.1,
130.7, 129.6, 129.0, 128.2, 128.2, 127.8, 127.6, 127.2, 121.9, 113.0,
112.3, 70.9, 67.1, 59.2, 54.1, 41.1, 23.9. IR (ATR): 3460, 3299, 2951,
2856, 2822, 1626, 1604, 1553, 1497, 1285, 1267, 1118, 1056 cm−1.
HRMS ESI−MS-q-TOF for [C27H29Br2N2O3]+ [M] found, 587.0556
m/z; calcd mass, 587.0545. Mp: 128.9 °C. UPLC−MS (DAD/ESI): tR
= 6.75 min, for [C27H29Br2N2O3]
+ [M] found, 587.12m/z; calcd mass,
587.05.
N-(2-((3-Bromo-4-((2-bromo-[1,1′-biphenyl]-3-yl)methoxy)-
benzyl)amino)ethyl)acetamide (2g). A solution of 2b (200 mg, 0.45
mmol), N-(2-aminoethyl)acetamide (209 mg, 2.05 mmol), and AcOH
(3 droplets) was stirred in anhydrous DMF (4 mL) at 25 °C for 2 h.
NaBH3CN (132 mg, 2.24 mmol) then was added, and the resulted
mixture was stirred additionally for 20 h. The residue was concentrated
under reduced pressure. Water was added (30 mL), and the mixture
was extracted with AcOEt (2 × 30 mL). Organic layers were combined,
dried over MgSO4, filtered, and concentrated. The crude product was
purified by column chromatography (silica gel, 0−30% MeOH in
CHCl3) to give an off-white solid (126 mg, yield: 53%) as a product.
1H
NMR (600 MHz, DMSO) δ: 7.84 (s, 1H), 7.66 (dd, J = 7.6, 1.6 Hz,
1H), 7.62 (d, J = 1.9 Hz, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.49−7.45 (m,
2H), 7.44−7.30 (m, 5H), 7.17 (d, J = 8.5 Hz, 1H), 5.26 (s, 2H), 3.68 (s,
2H), 3.14 (q, J = 6.3 Hz, 2H), 2.55 (t, J = 6.5 Hz, 2H), 1.79 (s, 3H). 13C
NMR (151 MHz, DMSO) δ: 169.7, 153.6, 143.4, 141.2, 137.0, 133.2,
131.3, 129.7, 129.3, 128.8, 128.6, 128.2, 122.9, 114.2, 111.4, 71.0, 51.5,
48.2, 38.7, 23.1. IR (ATR): 3280, 3051, 2937, 2829, 2659, 1654, 1556,
1499, 1445, 1369, 1282, 1259, 1056 cm−1. HRMS ESI−MS-q-TOF for
C24H24Br2N2O2 [M + H]
+ found, 531.0274m/z; calcd mass, 531.0283.
Mp: 142.9 °C. UPLC−MS (DAD/ESI): tR = 6.13 min, for
C24H24Br2N2O2 [M + H]
+ found, 531.22 m/z; calcd mass, 531.03.
(S)-1-(4-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-
piperidine-2-carboxylic Acid (2h). Compound 2h was prepared
following the protocol of 2g, using 2a (90 mg, 0.25 mmol), L-
pipecolinic acid (145 mg, 1.22 mmol), NaBH3CN (72mg, 1.23 mmol),
AcOH (3 droplets), and DMF (4 mL). The crude product was purified
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by flash chromatography (silica gel, 0−50%MeOH in CHCl3) to give a
white solid (77 mg, yield: 65%) as the product. 1H NMR (600 MHz,
DMSO) δ: 7.59 (d, J = 7.1 Hz, 1H), 7.54−7.25 (m, 9H), 7.04 (d, J = 7.9
Hz, 2H), 5.19 (s, 2H), 4.01 (d, J = 11.9 Hz, 1H), 3.11 (s, 1H), 2.98 (s,
1H), 2.40 (s, 1H), 1.87 (s, 1H), 1.69 (s, 1H), 1.61−1.43 (m, 3H), 1.35
(s, 1H). 13C NMR (151 MHz, DMSO) δ: 158.4, 143.5, 141.3, 137.2,
131.8, 131.4, 129.7, 129.5, 128.6, 128.2, 123.4, 115.0, 79.6, 70.3, 58.3,
49.6, 28.5, 23.9, 22.2. IR (ATR): 3055, 2940, 2862, 2352, 2251, 1610,
1513, 1447, 1413, 1386, 1242, 1180, 1028 cm−1. HRMS ESI−MS-q-
TOF for C26H26BrNO3 [M + H]
+ found, 480.1169 m/z; calcd mass,
480.1174. Mp: 182.5 °C. UPLC−MS (DAD/ESI): tR = 6.18 min, for
C26H26BrNO3 [M + H]
+ found, 480.24 m/z; calcd mass, 480.12.
(S ) -1- (4- ( (2 -Bromo-[1 ,1 ′ -b ipheny l ] -3-y l )methoxy) -3-
methylbenzyl)piperidine-2-carboxylic Acid (2i). Compound 2i was
obtained according to the procedure of 2g, using 2c (90 mg, 0.24
mmol), L-pipecolinic acid (140 mg, 1.08 mmol), NaBH3CN (69 mg,
1.18 mmol), AcOH (3 droplets), and DMF (4 mL). The crude product
was purified by flash chromatography (silica gel, 0−50% MeOH in
CHCl3) to give a yellow solid (65 mg, yield: 56%) as a product.
1H
NMR (600 MHz, CDCl3) δ: 7.50 (d, J = 7.5 Hz, 1H), 7.44−7.21 (m,
9H), 6.83 (d, J = 7.0 Hz, 1H), 5.06 (s, 2H), 4.39 (d, J = 55.8 Hz, 2H),
3.42 (d, J = 55.1 Hz, 2H), 2.62 (s, 1H), 2.28 (s, 3H), 1.96 (d, J = 9.0 Hz,
2H), 1.85−1.69 (m, 2H), 1.37−1.20 (m, 2H). 13C NMR (151 MHz,
CDCl3) δ: 157.8, 143.5, 141.3, 137.0, 134.3, 130.9, 130.6, 129.6, 128.1,
127.9, 127.8, 127.3, 127.2, 122.4, 111.6, 70.1, 58.5, 50.9, 29.8, 28.2,
22.8, 22.1, 16.7. IR (ATR): 2943, 2862, 2390, 2250, 1613, 1505, 1447,
1410, 1288, 1258, 1137, 1003 cm−1. HRMS ESI−MS-q-TOF for
C27H28BrNO3 [M + H]
+ found, 494.1325 m/z; calcd mass, 494.1330.
Mp: 106.3 °C. UPLC−MS (DAD/ESI): tR = 6.54 min, for
C27H28BrNO3 [M + H]
+ found, 494.26 m/z; calcd mass, 494.1330.
(S ) -1- (4- ( (2 -Bromo-[1 ,1 ′ -b ipheny l ] -3-y l )methoxy) -3-
methoxybenzyl)piperidine-2-carboxylic Acid (2j). Compound 2j was
obtained as described for 2g. Preparation involved the use of 2d (100
mg, 0.25 mmol), L-pipecolinic acid (149 mg, 1.15 mmol), NaBH3CN
(74 mg, 1.26 mmol), AcOH (3 droplets), and DMF (4 mL). The crude
product was purified by flash chromatography (silica gel, 0−50%
MeOH in CHCl3) to give a white solid (93 mg, yield: 72%) as a
product. 1HNMR (600MHz, DMSO) δ: 7.60 (dd, J = 7.6, 1.5 Hz, 1H),
7.52−7.33 (m, 7H), 7.09 (s, 1H), 7.05 (d, J = 8.2 Hz, 1H), 6.94 (d, J =
7.9 Hz, 1H), 5.17 (s, 2H), 4.08 (d, J = 12.8 Hz, 1H), 3.80 (s, 3H), 3.15
(s, 1H), 3.04 (s, 1H), 1.96−1.87 (m, 1H), 1.72 (d, J = 9.7 Hz, 1H),
1.61−1.53 (m, 3H), 1.41−1.33 (m, 1H). 13C NMR (151 MHz,
DMSO) δ: 149.4, 147.9, 143.4, 141.3, 137.4, 131.4, 129.7, 129.3, 128.6,
128.2, 123.3, 123.1, 114.5, 113.7, 79.6, 71.0, 58.5, 56.1, 49.7, 28.3, 23.6,
22.1. IR (ATR): 3345, 3055, 2939, 2867, 2394, 2251, 1633, 1606, 1517,
1448, 1416, 1268, 1238, 1102, 1029 cm−1. HRMS ESI−MS-q-TOF for
C27H28BrNO4 [M + H]
+ found, 510.1274 m/z; calcd mass, 510.1280.
Mp: 154.6 °C. UPLC−MS (DAD/ESI): tR = 6.10 min, for
C27H28BrNO4 [M + H]
+ found, 510.28 m/z; calcd mass, 510.13.
(S)-1-(3-Bromo-4-((2-bromo-[1,1′-biphenyl]-3-yl)methoxy)-
benzyl)piperidine-2-carboxylic Acid (2k). Compound 2k was
prepared following the protocol of 2g, using 2b (119 mg, 0.27
mmol), L-pipecolinic acid (158 mg, 1.22 mmol), NaBH3CN (79 mg,
1.33 mmol), and AcOH (3 droplets), which were stirred in DMF (4
mL). The crude product was purified by flash chromatography (silica
gel, 0−50%MeOH in CHCl3) to give a white solid (77 mg, yield: 51%)
as the product. 1H NMR (600 MHz, DMSO) δ: 7.67 (d, J = 6.5 Hz,
1H), 7.62 (s, 1H), 7.52 (t, J = 7.6 Hz, 1H), 7.50−7.35 (m, 6H), 7.32 (d,
J = 7.9 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 5.26 (s, 2H), 3.84 (d, J = 13.3
Hz, 1H), 3.49−3.39 (m, 1H), 3.05 (s, 1H), 2.90−2.83 (m, 1H), 2.24−
2.16 (m, 1H), 1.86−1.76 (m, 1H), 1.74−1.62 (m, 1H), 1.58−1.40 (m,
3H), 1.39−1.29 (m, 1H). 13C NMR (151 MHz, DMSO) δ: 153.4,
142.9, 140.7, 136.5, 133.7, 130.9, 129.8, 129.2, 128.3, 128.2, 127.7,
122.4, 113.6, 110.9, 70.6, 64.4, 57.8, 49.2, 28.7, 24.4, 22.0. IR (ATR):
3649, 3075, 2941, 2859, 2392, 2251, 1621, 1496, 1411, 1288, 1260,
1102, 1055 cm−1. HRMS ESI−MS-q-TOF for C26H25Br2NO3 [M +
Na]+ found, 580.0097 m/z; calcd mass, 580.0099. Mp: 129.1 °C.
UPLC−MS (DAD/ESI): tR = 6.51 min, for C26H25Br2NO3 [M + H]+
found, 558.20 m/z; calcd mass, 558.02.
4-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)-5-chloro-2-hydroxy-
benzaldehyde (3a). 5-Chloro-2,4-dihydroxybenzaldehyde (657 mg,
2.43 mmol) and NaHCO3 (200 mg, 2.43 mmoL) were dissolved in dry
ACN (13 mL) and stirred for 20 min. To the resulted mixture was
added dropwise 1a (528 mg, 1.62 mmol) in dry DMF (18 mL). The
solution was allowed to stir at room temperature for 20 h. The residue
was concentrated under reduced pressure. Water was added (60 mL),
and the mixture was extracted with AcOEt (2 × 60 mL). Organic layers
were combined, dried over MgSO4, filtered, and concentrated. The
crude product was purified by flash chromatography (silica gel, 0−
100% AcOEt in hexane) and yielded a white solid (368 mg, yield: 54%)
as a product. 1H NMR (600 MHz, CDCl3) δ: 11.43 (s, 1H), 9.72 (s,
1H), 7.62 (dd, J = 7.7, 0.7 Hz, 1H), 7.58 (s, 1H), 7.47−7.38 (m, 6H),
7.32 (dd, J = 7.5, 1.4 Hz, 1H), 6.61 (s, 1H), 5.30 (d, J = 4.3 Hz, 2H). 13C
NMR (151 MHz, CDCl3) δ: 193.9, 163.1, 160.7, 143.7, 141.1, 135.4,
134.2, 131.0, 129.6, 128.2, 127.9, 127.6, 127.1, 122.1, 115.4, 114.9,
102.0, 71.2 ppm. IR (ATR): 2925, 2850, 1644, 1618, 1490, 1360, 1274,
1200, 1056 cm−1. HRMS ESI−MS-q-TOF for C20H14BrClO3 [M +
Na]+ found, 438.9691 m/z; calcd mass, 438.9713. Mp: 192.8 °C.
UPLC−MS (DAD/ESI): tR = 9.34 min, for C20H14BrClO3 [M + H]+
found, 417.09 m/z; calcd mass, 416.99.
4-((5-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)-4-chloro-2-
formylphenoxy)methyl)picolinonitrile (3b). 3a (224 mg, 0.54 mmol),
4-(bromomethyl)picolinonitrile (235 mg, 1.19 mmol), and potassium
carbonate (507 mg, 3.67 mmol) were stirred in anhydrous DMF (18
mL) at room temperature overnight. The solvent was removed under
reduced pressure. Water was added (30 mL), and the mixture was
extracted with AcOEt (2 × 30 mL). Organic layers were combined and
concentrated. Purification involved flash chromatography (0−100%
AcOEt in hexane) and yielded 3b (180 mg, 63%) as a white solid. 1H
NMR (600 MHz, CDCl3) δ: 10.34 (s, 1H), 8.74 (d, J = 5.1 Hz, 1H),
7.95 (s, 1H), 7.72 (d, J = 0.7 Hz, 1H), 7.61−7.55 (m, 2H), 7.51−7.29
(m, 7H), 6.51 (s, 1H), 5.35 (s, 2H), 5.21 (s, 2H). 13C NMR (151MHz,
CDCl3) δ: 186.4, 159.9, 159.6, 151.7, 146.5, 143.8, 141.0, 135.3, 134.7,
131.3, 131.2, 129.5, 128.3, 128.1, 128.0, 127.4, 125.9, 124.3, 122.1,
119.7, 117.5, 117.0, 98.7, 71.1, 68.4. IR (ATR): 2923, 28853, 2237,
1677, 1598, 1500, 1444, 1380, 123, 1280, 1213, 1038 cm−1. HRMS
ESI−MS-q-TOF for C27H18BrClN2O3 [M + Na]+ found, 555.0107 m/
z; calcd mass, 555.0087. Mp: 199.7 °C. UPLC−MS (DAD/ESI): tR =
9.20 min, for C27H18BrClN2O3 [M + H]
+ found, 533.21 m/z; calcd
mass, 533.03.
3-((5-((2-Bromo-[1,1′-biphenyl]-3-yl)methoxy)-4-chloro-2-
formylphenoxy)methyl)benzonitrile (3c). Compound 3c was pre-
pared following the protocol of 3b, using 3a (135 mg, 0.33 mmol), 3-
(bromomethyl)benzonitrile (76 mg, 0.39 mmol), and potassium
carbonate (89 mg, 0.65 mmol), which were stirred in anhydrous
DMF (4 mL). Purification involved crystallization from AcOEt and
gave 2e (150mg, 87%) as a white solid. 1HNMR (600MHz, CDCl3) δ:
10.32 (s, 1H), 7.93 (s, 1H), 7.70 (s, 1H), 7.67−7.60 (m, 3H), 7.52 (t, J
= 7.7 Hz, 1H), 7.48−7.40 (m, 4H), 7.40−7.36 (m, 2H), 7.33 (dd, J =
7.5, 1.6 Hz, 1H), 6.57 (s, 1H), 5.32 (s, 2H), 5.18 (s, 2H). 13C NMR
(151 MHz, CDCl3) δ: 186.8, 160.7, 159.5, 143.7, 141.0, 137.2, 135.5,
132.3, 131.6, 131.2, 130.7, 130.5, 129.9, 129.5, 128.3, 128.0, 127.9,
127.4, 122.1, 119.7, 118.4, 117.0, 113.3, 98.9, 71.0, 70.0. IR (ATR):
2919, 2856, 2225, 1678, 1595, 1441, 1408, 1380, 1320, 1277, 1199,
1066 cm−1. HRMS ESI−MS-q-TOF for C28H19BrClNO3 [M + Na]+
found, 554.0112m/z; calcd mass, 554.0135.Mp: 189.4 °C. UPLC−MS
(DAD/ESI): tR = 9.64 min, for C28H19BrClNO3 [M + H]
+ found,
532.15 m/z; calcd mass, 532.03.
4-([1,1′:2′,1″-Terphenyl]-3′-ylmethoxy)-5-chloro-2-hydroxyben-
zaldehyde (3e). 5-Chloro-2,4-dihydroxybenzaldehyde (657 mg, 3.81
mmol), PPh3 (11.07 g, 42.21 mmol), and 1b (1000 mg, 3.84 mmol)
were dissolved in dry THF (30 mL). To the ice-cooled solution of the
resulted mixture was added dropwise DIAD (0.83 mL, 4.23 mmol) in
THF (30 mL). The solution was allowed to warm to room temperature
and was stirred for 20 h. The mixture was concentrated under reduced
pressure. The crude product was purified by column chromatography
on silica gel using 0−60% AcOEt in hexane to give a white solid (313
mg, yield: 20%). 1HNMR (600MHz, CDCl3) δ: 11.36 (s, 1H), 9.66 (s,
1H), 7.67 (d, J = 6.7 Hz, 1H), 7.54−7.48 (m, 2H), 7.45 (dd, J = 7.7, 1.2
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Hz, 1H), 7.24−7.06 (m, 10H), 6.26 (s, 1H), 4.93 (s, 2H). 13C NMR
(151 MHz, CDCl3) δ: 193.7, 162.8, 160.8, 142.0, 141.1, 139.9, 138.2,
133.9, 133.4, 130.3, 130.2, 129.8, 128.0, 127.9, 127.6, 127.2, 127.1,
126.4, 114.9, 114.7, 101.5, 69.7. IR (ATR): 3055, 2920, 2851, 1638,
1622, 1573, 1482, 1326, 1269, 1199, 1181, 1047 cm−1. HRMS ESI−
MS-q-TOF for C26H19ClO3 [M + Na]
+ found, 437.0915 m/z; calcd
mass, 437.0920. Mp: 152.4 °C. UPLC−MS (DAD/ESI): tR = 9.51 min,
for C26H19ClO3 [M + H]
+ found, 415.30 m/z; calcd mass, 415.11.
4-((5-([1,1′ :2′ ,1″-Terphenyl]-3′-ylmethoxy)-4-chloro-2-
formylphenoxy)methyl)picolinonitrile (3f). Compound 3f was
prepared following the protocol of 3b, using 3e (278 mg, 0.67
mmol), 4-(bromomethyl)picolinonitrile (159 mg, 0.81 mmol), K2CO3
(185 mg, 1.34 mmol), and anhydrous DMF (4 mL). The product was
isolated by crystallization from AcOEt as a white solid (175 mg, yield:
90%). 1H NMR (600 MHz, CDCl3) δ: 10.27 (s, 1H), 8.73 (d, J = 5.0
Hz, 1H), 7.88 (s, 1H), 7.66 (d, J = 0.6 Hz, 1H), 7.63 (dd, J = 7.5, 1.3 Hz,
1H), 7.52−7.44 (m, 3H), 7.23−7.19 (m, 3H), 7.18−7.12 (m, 3H),
7.10−7.02 (m, 4H), 6.14 (s, 1H), 5.04 (s, 2H), 4.95 (s, 2H). 13C NMR
(151 MHz, CDCl3) δ: 186.3, 159.7, 159.6, 151.5, 146.4, 142.1, 140.9,
139.8, 138.3, 134.5, 133.2, 130.9, 130.6, 130.3, 129.8, 128.1, 128.0,
127.7, 127.4, 127.2, 126.6, 125.8, 124.2, 119.2, 117.3, 116.9, 98.3, 69.8,
68.1. IR (ATR): 3060, 2875, 2242, 1673, 1595, 1499, 1449, 1402, 1320,
1278, 1263, 1166, 1034 cm−1. HRMS ESI−MS-q-TOF for
C33H23ClN2O3 [M + Na]
+ found, 553.1289 m/z; calcd mass,
553.1295. Mp: 196.7 °C. UPLC−MS (DAD/ESI): tR = 9.32 min, for
C33H23ClN2O3 [M + H]
+ found, 531.35 m/z; calcd mass, 531.15.
3-Bromo-4-((2-bromo-3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-
benzyl)oxy)benzaldehyde (4a). Compound 4a was prepared as
described in the protocol of 2a, using 1g (250 mg, 0.65 mmol), 3-
bromo-4-hydroxybenzaldehyde (130 mg, 0.65 mmol), potassium
carbonate (180 mg, 1.31 mmol), and anhydrous DMF (4 mL).
Crude product was purified by column chromatography on silica gel
(0−100% AcOEt in hexane) and yielded 4a (291 mg, 88%) as a white
solid. 1H NMR (600MHz, DMSO) δ: 9.88 (s, 1H), 8.15 (d, J = 2.0 Hz,
1H), 7.97 (dd, J = 8.5, 2.0 Hz, 1H), 7.64 (dd, J = 7.6, 1.6 Hz, 1H), 7.52−
7.44 (m, 2H), 7.35 (dd, J = 7.6, 1.7 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H),
6.87 (d, J = 2.1 Hz, 1H), 6.84 (dd, J = 8.2, 2.1 Hz, 1H), 5.40 (s, 2H),
4.29 (s, J = 4.6 Hz, 4H). 13C NMR (151MHz, DMSO) δ: 190.7, 159.0,
143.2, 142.9, 142.5, 135.8, 134.1, 133.8, 131.3, 131.2, 131.0, 128.5,
127.8, 122.9, 122.3, 118.0, 116.8, 114.1, 111.9, 71.2, 64.2. IR (ATR):
2983, 2952, 1685, 1598, 1494, 1314, 1275, 1258, 1243, 1190, 1062
cm−1. HRMS ESI−MS-q-TOF for C22H16Br2O4 [M + Na]+ found,
524.9348 m/z; calcd mass, 524.9313. Mp: 196.2 °C. UPLC−MS
(DAD/ESI): tR = 8.98 min, for C22H16Br2O4 [M + H]
+ found, 503.04
m/z; calcd mass, 502.95.
(S)-1-(3-Bromo-4-((2-bromo-3-(2,3-dihydrobenzo[b][1,4]dioxin-
6-yl)benzyl)oxy)benzyl)piperidine-2-carboxylic Acid (4b). Com-
pound 4b was prepared according to the procedure of 2g, using 4a
(310 mg, 0.61 mmol), L-pipecolinic acid (364 mg, 2.82 mmol),
NaBH3CN (181 mg, 3.07 mmol), addition of AcOH (3 droplets), and
anhydrous DMF (4mL) as a solvent. The crude product was purified by
flash chromatography (silica gel, 0−50% MeOH in CHCl3) to give a
white solid (164 mg, yield: 43%) as the product. 1H NMR (600 MHz,
DMSO) δ: 7.66−7.59 (m, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.35−7.29 (m,
2H), 7.18 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.2 Hz, 1H), 6.86 (d, J = 2.1
Hz, 1H), 6.83 (dd, J = 8.3, 2.1 Hz, 1H), 5.24 (s, 2H), 4.28 (s, 4H), 3.85
(d, J = 13.4 Hz, 1H), 3.06 (dd, J = 8.2, 3.8 Hz, 1H), 2.93−2.81 (m, 1H),
2.30−2.17 (m, J = 16.9, 8.1 Hz, 1H), 1.86−1.77 (m, 1H), 1.74−1.61
(m, J = 12.6, 6.6 Hz, 1H), 1.57−1.41 (m, 3H), 1.38−1.28 (m, 1H), 1.23
(s, 1H). 13C NMR (151 MHz, DMSO) δ: 153.6, 143.1, 142.8, 142.4,
136.5, 133.8, 133.7, 131.0, 129.9, 128.2, 127.7, 122.7, 122.3,
118.0,116.8, 113.7, 111.0, 70.7, 64.2, 57.9, 49.2, 28.6, 28.5, 24.1, 22.0.
IR (ATR): 2932, 2864, 2356, 2323, 2286, 1728, 1634, 1589, 1500,
1454, 1368, 1315, 1278, 1260, 1246, 1197, 1065 cm−1. HRMS ESI−
MS-q-TOF for C28H27Br2NO5 [M + H]
+ found, 616.0327 m/z; calcd
mass, 616.0334. Mp: decomposition at 191.9 °C. UPLC−MS (DAD/
ESI): tR = 6.25 min, for C28H27Br2NO5 [M + H]
+ found, 616.23 m/z;
calcd mass, 616.03.
3-Bromo-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-
fluorobenzyl)oxy)benzaldehyde (4c). 1d (700 mg, 2.69 mmoL) was
dissolved in anhydrous DCM (10 mL) under Ar. SOCl2 (3.2 mL) was
added carefully, and the resulted mixture was stirred at 45 °C. After 3 h
the reaction was stopped, and the mixture was concentrated under
reduced pressure. Generated in situ chloride, 3-bromo-4-hydroxyben-
zaldehyde (1.6 g, 8.08 mmol), and K2CO3 (1.8 g, 13.46 mmol) were
stirred in anhydrous DMF (10 mL) at room temperature overnight.
The solvent was removed under reduced pressure. Water was added
(100 mL), and the mixture was extracted with AcOEt (2 × 100 mL).
Organic layers were combined and concentrated. The crude product
was chromatographed on silica gel eluting with 0−60% AcOEt in
hexane to give 180 mg of a white solid with a yield of 30%. 1H NMR
(600MHz, CDCl3) δ: 9.85 (s, 1H), 8.12 (d, J = 2.0 Hz, 1H), 7.81 (dd, J
= 8.5, 2.0 Hz, 1H), 7.55 (t, J = 7.1 Hz, 1H), 7.39 (td, J = 7.6, 1.6 Hz,
1H), 7.23 (t, J = 7.7 Hz, 1H), 7.12 (d, J = 8.5 Hz, 1H), 7.09 (t, J = 1.7
Hz, 1H), 7.04 (dt, J = 8.3, 1.8 Hz, 1H), 6.95 (d, J = 8.4 Hz, 1H), 5.36 (s,
2H), 4.31 (s, 4H). 13C NMR (151 MHz, CDCl3) δ: 189.7, 159.7, 157.0
(d, 1JC−F = 248.2 Hz), 143.6 (d,
2JC−F = 14.0 Hz), 134.8, 131.3, 131.2,
130.7 (d, 3JC−F = 3.1 Hz), 128.8, 128.7, 128.7, 127.8 (d,
3JC−F = 3.1 Hz),
124.7 (d, 3JC−F = 3.8 Hz), 123.6 (d,
2JC−F = 15.1 Hz), 122.4, 118.1,
117.5, 113.4, 113.0, 65.2 (d, 3JC−F = 6.3 Hz), 64.6, 64.5. IR (ATR):
2927, 2823, 2738, 1691, 1592, 1493, 1450, 1323, 1278, 1191, 1064,
1047 cm−1. HRMS ESI−MS-q-TOF for C22H16BrFO4 [M + Na]+
found, 465.0109m/z; calcd mass, 465.0114.Mp: 118.0 °C. UPLC−MS
(DAD/ESI): tR = 8.56 min, for C22H16BrFO4 [M + H]
+ found, 443.15
m/z; calcd mass, 443.03.
N-(2-((3-Bromo-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-
fluorobenzyl)oxy)benzyl)amino)ethyl)acetamide (4d). Compound
4d was prepared following the procedure of 2g, using 4c (120 mg,
0.27 mmol), N-(2-aminoethyl)acetamide (126 mg, 1.24 mmol),
NaBH3CN (79 mg, 1.35 mmol), addition of AcOH (3 droplets), and
anhydrous DMF (4mL) as a solvent. The crude product was purified by
column chromatography (silica gel, 0−30%MeOH in CHCl3) to give a
white solid (88 mg, yield: 61%) as the product. 1H NMR (600 MHz,
CDCl3) δ: 7.60 (d, J = 2.0 Hz, 1H), 7.55 (t, J = 6.4 Hz, 1H), 7.36 (td, J =
7.6, 1.6 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.08
(t, J = 1.5 Hz, 1H), 7.04 (dt, J = 8.4, 1.8 Hz, 1H), 6.97 (d, J = 8.4 Hz,
1H), 6.94 (d, J = 8.4 Hz, 1H), 6.30 (s, 1H), 5.25 (s, 2H), 4.30 (s, 4H),
3.79 (s, 2H), 3.39 (dd, J = 11.1, 5.5 Hz, 2H), 2.84 (t, J = 5.6 Hz, 2H),
2.00 (s, 3H). 13C NMR (151 MHz, CDCl3) δ: 171.0, 157.0 (d,
1JC−F =
248.1 Hz), 154.6, 143.6 (d, 3JC−F = 6.9 Hz), 133.8, 131.5, 130.4 (d,
4JC−F = 2.6 Hz), 129.1, 128.8, 128.6 (d,
2JC−F = 13.3 Hz), 127.9 (d,
3JC−F
= 3.2 Hz), 124.5 (d, 3JC−F = 3.7 Hz), 124.4 (d,
2JC−F = 15.2 Hz), 122.4,
118.1, 117.4, 113.9, 112.8, 65.0 (d, 3JC−F = 6.0 Hz), 64.6, 64.5, 52.1,
47.9, 38.7, 23.4. IR (ATR): 3283, 2925, 2803, 2163, 1692, 1655, 1578,
1502, 1454, 1417, 1373, 1319, 1283, 1261, 1244, 1192, 1128, 1066,
1048 cm−1. HRMS ESI−MS-q-TOF for C26H26BrFN2O4 [M + H]+
found, 529.1135m/z; calcd mass, 529.1138.Mp: 121.6 °C. UPLC−MS
(DAD/ESI): tR = 5.66 min, C26H26BrFN2O4 [M + H]
+ found, 529.22
m/z; calcd mass, 529.11.
4-([1,1′:2′,1″-Terphenyl]-3′-ylmethoxy)-3-bromobenzaldehyde
(4e). Compound 4e was prepared following the procedure of 4c.
Preparation of chloride involved the use of 1b (300 mg, 1.15 mmoL),
which was dissolved in anhydrous DCM (4.5 mL) with the addition of
SOCl2 (1.4 mL) under Ar. In the second step, generated in situ chloride
was stirred with 3-bromo-4-hydroxybenzaldehyde (231 mg, 1.15
mmol) and K2CO3 (319 mg, 2.31 mmol) in anhydrous DMF (3.3
mL) at room temperature overnight. The crude product was
chromatographed on silica gel, eluting with 0−60% AcOEt in hexane
to give 308 mg of an off-white solid with yield: 60%. 1H NMR (600
MHz, CDCl3) δ: 9.8 (s, 1H), 8.1 (d, J = 2.0 Hz, 1H), 7.7 (m, 1H), 7.7
(dd, J = 8.5, 2.0 Hz, 1H), 7.5 (t, J = 7.7 Hz, 1H), 7.4 (dd, J = 7.7, 1.2 Hz,
1H), 7.2−7.0 (m, 10H), 6.7 (d, J = 8.5 Hz, 1H), 5.0 (s, 2H). 13C NMR
(151 MHz, CDCl3) δ: 189.7, 159.8, 142.0, 141.3, 139.8, 138.4, 134.7,
133.9, 131.1, 130.9, 130.4, 130.3, 129.9, 128.1, 128.0, 127.7, 127.3,
127.2, 126.5, 113.2, 112.9, 69.7. IR (ATR): 3029, 2733, 1685, 1592,
1285, 1263, 1194, 1005 cm−1. HRMS ESI−MS-q-TOF for C26H19BrO2
[M + Na]+ found, 465.0465 m/z; calcd mass, 465.0466. Mp: 142.3 °C.
UPLC−MS (DAD/ESI): tR = 9.51 min, for C26H19BrO2 [M + H]+
found, 445.34 m/z; calcd mass, 445.06.
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(2S,4S)-1-(4-([1,1′:2′,1″-Terphenyl]-3′-ylmethoxy)-3-bromoben-
zyl)-4-hydroxypyrrolidine-2-carboxylic Acid (4f). The synthesis of
compound 4f was performed following the procedure of 2g.
Preparation included the use of 4e (200 mg, 0.45 mmol), (2R,4R)-4-
hydroxypyrrolidine-2-carboxylic acid (272 mg, 2.07 mmol), NaBH3CN
(142 mg, 2.26 mmol), AcOH (3 droplets), and anhydrous DMF (6.0
mL). The crude product was purified by flash chromatography (silica
gel, 0−50%MeOH in AcOEt) to give a white solid (93 mg, yield: 37%)
as the product. 1H NMR (600 MHz, CDCl3) δ: 7.7 (d, J = 7.2 Hz, 1H),
7.6−7.5 (m, 2H), 7.4 (dd, J = 7.7, 1.1 Hz, 1H), 7.2−7.1 (m, 9H), 7.1−
7.0 (m, 2H), 6.7 (d, J = 8.4 Hz, 1H), 4.8 (s, 2H), 4.1 (s, 1H), 3.9 (d, J =
13.1 Hz, 1H), 3.5 (d, J = 13.0 Hz, 1H), 3.1 (s, J = 19.4 Hz, 1H), 2.8 (d, J
= 9.4 Hz, 1H), 2.4 (s, 1H), 2.2 (s, 1H), 1.7 (d, J = 8.8 Hz, 1H), 1.2 (s,
1H). 13CNMR (151MHz, CDCl3) δ: 153.4, 141.3, 141.0, 139.8, 138.0,
134.6, 133.6, 130.1, 129.9, 129.7, 129.5, 129.0, 127.8, 127.7, 127.7,
127.7, 126.9, 126.4, 113.2, 110.7, 68.8, 68.6, 65.4, 60.7, 55.8, 48.6. IR
(ATR): 3297, 3057, 2659, 1600, 1494, 1410, 1253, 1050 cm−1. HRMS
ESI−MS-q-TOF for C31H28BrNO4 [M + Na]+ found, 580.1078 m/z;
calcd mass, 580.1099. Mp: 152.3 °C. UPLC−MS (DAD/ESI): tR =
6.55 min, for C31H28BrNO4 [M + H]
+ found, 558.27 m/z; calcd mass,
558.13.
2′-Bromo-3′-((2-bromo-4-formylphenoxy)methyl)-[1,1′-biphen-
yl]-4-carbonitrile (4g). The synthesis of compound 4g was performed
according to the procedure of 2a, using 1e (559 mg, 1.59 mmol), 3-
bromo-4-hydroxybenzaldehyde (320 mg, 1.59 mmol), potassium
carbonate (440 mg, 3.18 mmol), and anhydrous DMF (8 mL). The
product was precipitated from AcOEt and yielded 4g (461 mg, 61%) as
a white solid. 1H NMR (600 MHz, CDCl3) δ: 9.88 (s, 1H), 8.15 (d, J =
2.0 Hz, 1H), 7.84 (dd, J = 8.4, 2.0 Hz, 1H), 7.79−7.73 (m, 3H), 7.53−
7.50 (m, 2H), 7.48 (t, J = 7.7 Hz, 1H), 7.28 (dd, J = 7.6, 1.6 Hz, 1H),
7.11 (d, J = 8.5 Hz, 1H), 5.34 (s, 2H). 13C NMR (151 MHz, CDCl3) δ:
189.6, 159.4, 145.6, 141.7, 136.3, 134.9, 132.1, 131.4, 131.3, 130.5,
128.3, 128.0, 121.3, 118.8, 113.4, 113.1, 111.9, 70.9. IR (ATR): 2844,
2227, 1688, 1590, 1566, 1489, 1276, 1256, 1184, 1050 cm−1. HRMS
ESI−MS-q-TOF for C21H13Br2NO2 [M + Na]+ found, 491.9203 m/z;
calcd mass, 491.9211. Mp: over 200 °C. UPLC−MS (DAD/ESI): tR =
8.71 min, for C21H13Br2NO2 [M + H]
+ found, 469.93 m/z; calcd mass,
469.94.
N-(2-((3-Bromo-4-((2-bromo-4′-cyano-[1,1′-biphenyl]-3-yl)-
methoxy)benzyl)amino)ethyl)acetamide (4h). Compound 4h was
prepared following the procedure of 2g, using 4g (100 mg, 0.21 mmol),
N-(2-aminoethyl)acetamide (99 mg, 0.97 mmol), NaBH3CN (63 mg,
1.06 mmol), addition of AcOH (3 droplets), and anhydrous DMF (5
mL) as a solvent. The crude product was purified by column
chromatography (silica gel, 0−30% MeOH in CHCl3) to give an off-
white solid (30 mg, yield: 26%) as a product. 1H NMR (600 MHz,
CDCl3) δ: 7.79 (d, J = 7.7 Hz, 1H), 7.74 (d, J = 8.3 Hz, 2H), 7.58 (d, J =
1.9 Hz, 1H), 7.51 (d, J = 8.3 Hz, 2H), 7.46 (t, J = 7.7 Hz, 1H), 7.25 (dd,
J = 7.6, 1.5 Hz, 1H), 7.21 (dd, J = 8.3, 1.9 Hz, 1H), 6.94 (d, J = 8.4 Hz,
1H), 6.00 (s, 1H), 5.23 (s, 2H), 3.73 (s, 2H), 3.35 (dd, J = 11.3, 5.6 Hz,
2H), 2.76 (t, J = 5.8 Hz, 2H), 1.99 (s, 3H). 13C NMR (151 MHz,
CDCl3) δ: 170.5, 153.9, 145.8, 141.5, 137.3, 134.5, 133.3, 132.1, 130.5,
130.1, 128.4, 128.4, 127.9, 121.2, 118.9, 113.7, 112.5, 111.8, 70.8, 52.5,
48.1, 39.2, 23.5. IR (ATR): 3282, 2925, 2228, 1688, 1654, 1591, 1554,
1490, 1447, 1362, 1279, 1256, 1185, 1052, 1025 cm−1. HRMS ESI−
MS-q-TOF for C25H23Br2N3O2 [M + H]
+ found, 556.0230 m/z; calcd
mass, 556.0235. Mp: 152.8 °C. UPLC−MS (DAD/ESI): tR = 5.67 min,
for C25H23Br2N3O2 [M + H]
+ found, 556.21 m/z; calcd mass, 556.02.
3-Bromo-4-((2-bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)methoxy)-
benzaldehyde (4i). Compound 4i was obtained according to the
procedure of 2a, using 1f (700 mg, 2.03 mmol), 4-hydroxy-3-
methylbenzaldehyde (409 mg, 2.03 mmol), potassium carbonate
(562 mg, 4.07 mmol), and anhydrous DMF (10 mL). Product was
purified by precipitation from AcOEt and yielded 4i (534mg, 57%) as a
white solid. 1H NMR (600 MHz, CDCl3) δ: 9.87 (s, 1H), 8.15 (d, J =
2.0 Hz, 1H), 7.83 (dd, J = 8.4, 2.0 Hz, 1H), 7.75−7.69 (m, 1H), 7.44 (t,
J = 7.6 Hz, 1H), 7.42−7.38 (m, 1H), 7.30 (dd, J = 7.5, 1.7 Hz, 1H),
7.19−7.14 (m, 1H), 7.14−7.05 (m, 3H), 5.35 (s, 2H). 13C NMR (151
MHz, CDCl3) δ: 189.6, 162.5 (d,
1JC−F = 246.4 Hz), 159.5, 143.1 (d,
3JC−F = 7.9 Hz), 142.3, 135.9, 134.8, 131.3, 130.7, 129.8 (d,
3JC−F = 8.3
Hz), 127.8, 127.6, 125.4 (d, 4JC−F = 2.2 Hz), 121.7, 116.8 (d,
2JC−F =
22.0 Hz), 114.8 (d, 2JC−F = 21.0 Hz), 113.4, 113.1, 71.0. IR (ATR):
3060, 2922, 2853, 1683, 1594, 1490, 1461, 1418, 1368, 1313, 1278,
1255, 1190, 1049 cm−1. HRMS ESI−MS-q-TOF for C20H13Br2FO2 [M
+ Na]+ found, 484.9150 m/z; calcd mass, 484.9164. Mp: 168.1 °C.
UPLC−MS (DAD/ESI): tR = 9.32 min, for C20H13Br2FO2 [M + H]+
found, 463.02 m/z; calcd mass, 462.93.
(S)-1-(3-Bromo-4-((2-bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)-
methoxy)benzyl)piperidine-2-carboxylic Acid (4j).Compound 4jwas
prepared following the procedure of 2g, using 4i (135 mg, 0.29 mmol),
L-pipecolinic acid (172 mg, 1.33 mmol), NaBH3CN (86 mg, 1.45
mmol), addition of AcOH (3 droplets), and anhydrous DMF (5mL) as
a solvent. The crude product was purified by column chromatography
(silica gel, 0−40%MeOH in CHCl3) to give a white solid (73mg, yield:
44%) as the product. 1H NMR (600 MHz, DMF) δ: 7.82 (dd, J = 7.7,
1.5 Hz, 1H), 7.73 (s, 1H), 7.63−7.56 (m, 2H), 7.46−7.41 (m, 2H),
7.33−7.27 (m, 4H), 5.36 (s, 2H), 3.97 (d, J = 13.3 Hz, 1H), 3.56 (d, J =
12.8 Hz, 1H), 3.29−3.23 (m, 1H), 3.03−2.97 (m, 1H), 2.39−2.30 (m,
1H), 1.95−1.89 (m, 1H), 1.85−1.77 (m, 1H), 1.62−1.48 (m, 3H),
1.48−1.39 (m, 1H). 13C NMR (151 MHz, DMF) δ: 175.0, 167.2 (d,
1JC−F = 63.5 Hz), 155.0, 144.4 (d,
3JC−F = 7.9 Hz), 143.1, 138.1, 134.9,
131.9, 131.2 (d, 3JC−F = 8.4 Hz), 130.9, 129.8, 128.9, 126.7, 123.2, 117.4
(d, 2JC−F = 22.2Hz), 115.6 (d,
2JC−F = 21.0 Hz), 114.7, 112.3, 71.9, 65.4,
59.4, 50.5, 25.7, 24.0, 23.2. IR (ATR): 2923, 2853, 1614, 1495, 1461,
1363, 1288, 1259, 1196, 1157, 1055, 1023 cm−1. HRMS ESI−MS-q-
TOF for C26H24Br2FNO3 [M + H]
+ found, 576.0180 m/z; calcd mass,
576.0185. Mp: 175.6 °C. UPLC−MS (DAD/ESI): tR = 6.65 min, for
C26H24Br2FNO3 [M + H]
+ found, 576.15 m/z; calcd mass, 576.02.
N-(2-((3-Bromo-4-((2-bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)-
methoxy)benzyl)amino)ethyl)acetamide (4k). Compound 4k was
prepared according to the procedure of 2g, using 4i (200 mg, 0.43
mmol), N-(2-aminoethyl)acetamide (201 mg, 1.97 mmol), NaBH3CN
(127 mg, 2.16 mmol), addition of AcOH (3 droplets), and anhydrous
DMF (4 mL) as a solvent. The crude product was purified by column
chromatography (silica gel, 0−40% MeOH in CHCl3) to give a white
solid (159 mg, yield: 67%) as the product. 1H NMR (600 MHz,
DMSO) δ: 7.98 (t, J = 5.2 Hz, 1H), 7.70 (d, J = 1.9 Hz, 1H), 7.68 (dd, J
= 7.7, 1.6 Hz, 1H), 7.56−7.49 (m, 2H), 7.41−7.37 (m, 2H), 7.30−7.19
(m, 4H), 5.27 (s, 2H), 3.81 (s, 2H), 3.21 (dd, J = 12.2, 6.2 Hz, 2H), 2.67
(t, J = 6.4 Hz, 2H), 1.80 (s, 3H). 13C NMR (151 MHz, DMSO) δ:
169.6, 161.7 (d, 1JC−F = 244.0 Hz), 153.6, 142.9 (d,
3JC−F = 8.0 Hz),
141.7, 136.6, 133.4, 130.9, 130.3 (d, 3JC−F = 8.5 Hz), 129.6, 128.8,
127.9, 125.6, 122.3, 116.3 (d, 2JC−F = 22.0 Hz), 114.7 (d,
2JC−F = 20.8
Hz), 113.8, 111.0, 70.6, 50.4, 47.2, 37.3, 22.7. IR (ATR): 3282, 2934,
2774, 2427, 1656, 1557, 1500, 1446, 1363, 1291, 1261, 1195, 1070,
1056 cm−1. HRMS ESI−MS-q-TOF for C24H23Br2FN2O2 [M + H]+
found, 549.0176m/z; calcd mass, 549.0189.Mp: 151.2 °C. UPLC−MS
(DAD/ESI): tR = 6.21 min, for C24H23Br2FN2O2 [M + H]
+ found,
549.16 m/z; calcd mass, 549.02.
4-(3-Bromo-4-((2-bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)-
methoxy)benzyl)thiomorpholine 1,1-Dioxide (4l). The synthesis of
compound 4l was performed following the procedure of 2g.
Preparation included the use of 4i (100 mg, 0.22 mmol), thiomorpho-
line 1,1-dioxide (133 mg, 0.99 mmol), NaBH3CN (64 mg, 1.08 mmol),
AcOH (3 droplets), and anhydrous DMF (4.0 mL). The crude product
was purified by column chromatography (silica gel, 0−10% MeOH in
CHCl3) to give an off-white solid (41 mg, yield: 33%) as a product.
1H
NMR (600 MHz, CDCl3) δ: 7.75 (dd, J = 7.7, 0.7 Hz, 1H), 7.57 (d, J =
2.0 Hz, 1H), 7.41 (m, 2H), 7.28 (dd, J = 7.5, 1.5 Hz, 1H), 7.20 (dd, J =
8.4, 2.0 Hz, 1H), 7.16 (d, J = 7.6 Hz, 1H), 7.13−7.08 (m, 2H), 6.95 (d, J
= 8.4 Hz, 1H), 5.25 (s, 2H), 3.58 (s, 2H), 3.08−3.05 (m, 4H), 2.99−
2.96 (m, 4H). 13C NMR (151 MHz, CDCl3) δ: 162.4 (d,
1JC−F = 246.1
Hz), 154.4, 143.2 (d, 3JC−F = 7.9 Hz), 142.2, 136.8, 133.8, 131.7, 130.4,
129.7 (d, 3JC−F = 8.3 Hz), 129.0, 127.7, 127.7, 125.4, 121.6, 116.8 (d,
2JC−F = 22.0 Hz), 114.8 (d,
2JC−F = 21.0 Hz), 113.6, 112.7, 70.9, 60.5,
51.6, 50.7. IR (ATR): 3079, 2818, 1608, 1584, 1494, 1463, 1363, 1328,
1301, 1253, 1199, 1124, 1110 cm−1. HRMS ESI−MS-q-TOF for
C24H22Br2FNO3S [M + Na]
+ found, 603.9573 m/z; calcd mass,
603.9569. Mp: 183.0 °C. UPLC−MS (DAD/ESI): tR = 8.81 min, for
C24H22Br2FNO3S [M + H]
+ found, 582.13 m/z; calcd mass, 581.97.
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(3-((2-Bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)methoxy)phenyl)-
methanol (4m).Compound 4mwas obtained following the protocol of
2a, using 1f (700 mg, 2.03 mmol), 3-(hydroxymethyl)phenol (252 mg,
2.03mmol), potassium carbonate (562mg, 4.07mmol), and anhydrous
DMF (10mL). Crude product was purified by column chromatography
on silica gel (0−100% AcOEt in hexane) and yielded 4m (408 mg,
52%) as a white solid. 1H NMR (600 MHz, CDCl3) δ: 7.61−7.57 (m,
1H), 7.44−7.37 (m, 2H), 7.31 (t, J = 7.9 Hz, 1H), 7.27 (d, J = 1.7 Hz,
1H), 7.19−7.16 (m, 1H), 7.14−7.08 (m, 2H), 7.07 (s, 1H), 7.00 (dd, J
= 7.5, 0.6 Hz, 1H), 6.95 (dd, J = 8.2, 2.4 Hz, 1H), 5.21 (s, 2H), 4.70 (d, J
= 5.8Hz, 2H), 1.73 (t, J = 6.0 Hz, 1H). 13CNMR (151MHz, CDCl3) δ:
162.4 (d, 1JC−F = 246.2 Hz), 158.9, 143.4 (d,
3JC−F = 7.9 Hz), 142.8,
142.3, 137.4, 130.5, 129.9, 129.7 (d, 3JC−F = 8.3 Hz), 128.1, 127.5, 125.4
(d, 4JC−F = 2.3 Hz), 122.4, 119.9, 116.8 (d,
2JC−F = 22.0 Hz), 114.7 (d,
2JC−F = 21.0 Hz), 114.2, 113.5, 70.2, 65.4. IR (ATR): 3233, 2854, 1601,
1584, 1493, 1448, 1417, 1365, 1258, 1196, 1173, 1155, 1068, 1055
cm−1. HRMS ESI−MS-q-TOF for C20H16BrFO2 [M + Na]+ found,
409.0207m/z; calcd mass, 409.0215. Mp: 59.0 °C. UPLC−MS (DAD/
ESI): tR = 8.05min, for C20H16BrFO2 [(M−H2O) +H]+ found, 369.17
m/z; calcd mass, 369.02.
4-(3-((2-Bromo-3′-fluoro-[1,1′-biphenyl]-3-yl)methoxy)benzyl)-
thiomorpholine 1,1-Dioxide (4n). Compound 4m (100 mg, 0.26
mmoL) was dissolved in anhydrous DCM (3mL) under Ar. SOCl2 (1.0
mL) was added carefully, and the resulted mixture was stirred at 45 °C
for 3 h. Afterward, the reaction was stopped, and the mixture was
concentrated under reduced pressure. Generated in situ chloride,
thiomorpholine 1,1-dioxide (105 mg, 0.78 mmol), and K2CO3 (178
mg, 1.29 mmol) were stirred in anhydrous DMF (5 mL) at room
temperature overnight. The solvent was removed under reduced
pressure.Water was added (30mL), and the mixture was extracted with
AcOEt (2 × 30 mL). Organic layers were combined and concentrated.
The crude product was chromatographed on silica gel eluting with 0−
60% AcOEt in hexane to give 38 mg of an off-white solid with a yield of
29%. 1H NMR (600 MHz, CDCl3) δ: 7.58 (dd, J = 7.6, 1.0 Hz, 1H),
7.44−7.37 (m, 2H), 7.31−7.27 (m, 2H), 7.17 (d, J = 7.6 Hz, 1H),
7.13−7.08 (m, 2H), 6.99 (s, 1H), 6.94 (m, 2H), 5.20 (s, 2H), 3.65 (s,
2H), 3.08−3.03 (m, 4H), 2.99 (m, 4H). 13C NMR (151 MHz, CDCl3)
δ: 162.4 (d, 1JC−F = 246.2 Hz), 158.9, 143.3 (d,
3JC−F = 8.0 Hz), 142.4,
139.3, 137.3, 130.5, 129.9, 129.7 (d, 3JC−F = 8.3 Hz), 128.1, 127.5,
125.4, 122.4, 121.7, 116.8 (d, 2JC−F = 22.0 Hz), 115.5, 114.8 (d,
2JC−F =
20.9 Hz), 114.0, 70.2, 61.5, 51.7, 50.8. IR (ATR): 2918, 2849, 1583,
1487, 1462, 1364, 1290, 1269, 1195, 1153, 1123, 1049 cm−1. HRMS
ESI−MS-q-TOF for C24H23BrFNO3S [M + Na]+ found, 526.0454 m/
z; calcd mass, 526.0464. Mp: 94.2 °C. UPLC−MS (DAD/ESI): tR =
8.28 min, for C24H23BrFNO3S [M + H]
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